← FDA DRUG APPROVALS

FDA ANDA · ANDA209839

SOLIFENACIN SUCCINATE

Sponsor: CIPLA

APPLICATION
ANDA209839
TYPE
ANDA
ORIGINAL APPROVAL
2019-05-20
LATEST ACTION
2020-11-24
ROUTE
ORAL
DOSAGE FORM
TABLET
MARKETING STATUS
Discontinued

Products

SOLIFENACIN SUCCINATEDiscontinued
SOLIFENACIN SUCCINATE 10MG · TABLET · ORAL
SOLIFENACIN SUCCINATEDiscontinued
SOLIFENACIN SUCCINATE 5MG · TABLET · ORAL

Approval history

2020-11-24Labeling · Supplement 4 · standardAP
2019-05-20UNKNOWN · Original · standardAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →